Oncology
Conditions
Keywords
Oxaliplatin induced peripheral neurotoxicity, Clinical curative effect
Brief summary
To evaluate the efficacy and safety of Huangqi Guizhi Wuwu decoction in preventing oxaliplatin induced peripheral neurotoxicity.
Detailed description
The purpose of this study is to evaluate whether the preventive effect of Huangqi Guizhi Wuwu decoction on oxaliplatin induced peripheral neurotoxicity is better than that of simulator, and to provide evidence-based medicine basis for the clinical promotion of single medicine granule. This trial purpose is to evaluate the efficacy and safety of Huangqi Guizhi Wuwu decoction in preventing oxaliplatin induced peripheral neurotoxicity. This trial design type is a randomized, controlled, double-blind, multicenter clinical study was conducted.
Interventions
The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles). The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).
Sponsors
Jiangsu Famous Medical Technology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Patients with colorectal cancer diagnosed by histopathological examination; patients after radical resection of colorectal cancer confirmed by histopathological examination, staged as high-risk II stage
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1\. Patients with colorectal cancer diagnosed by histopathological examination; patients after radical resection of colorectal cancer confirmed by histopathological examination, staged as high-risk II stage (according to CSCO guidelines for diagnosis and treatment of colorectal cancer) or III stage, IV stage (metastatic lesions have been radical resection); 2. Patients who are suitable for receiving oxaliplatin plus capecitabine regimen as adjuvant chemotherapy for 6 months, the cumulative dose of oxaliplatin are expected to exceed 520mg/m2 at least; 3. Aged from 18 to 75 years old, males or females; 4. ECOG score ranges from 0 to 1 5. Seven days before treatment, the functions of major organs (heart, liver, kidney, bone marrow) meet the following criteria: 1. Standard of blood routine examination (without blood transfusion within 14 days) i. Hemoglobin (HB) ≥90g/L； ii. Absolute Neutrophil Count(ANC) ≥1.5×109/L；. iii. Platelet (PLT) ≥80×109/L. 2. Biochemical examination should meet the following standards: * Total bilirubin(TBIL) ≤1.5 times upper normal limit(ULN); * Alanine aminotransferase(ALT) and Aspartate aminotransferase(AST) ≤2.5 times ULN； ③Serum creatinine （Cr）≤1.5 times ULN or Creatinine clearance(CCr) ≥60ml/min; 6.Expected survival time≥12 months; 7. For subjects who have used other chemotherapeutic drugs in the past, they need to go through a clearance period of at least 4 weeks before entering this trial. 8\. The patient who will sign the informed consent form
Exclusion criteria
1. Patients with original nervous system diseases, including peripheral neuropathy and central neuropathy; 2. Those who are allergic to oxaliplatin or the ingredients of this traditional Chinese medicine; 3. Clinical symptoms of patients with severe damp-heat syndrome of colorectal cancer include: dry mouth, bitter taste in the mouth, sticky sensation in mouth, yellow urine, dry stool, red tongue with yellow ,thick and greasy fur; 4. Patients with neurological disease caused by electrolyte disorders or diabetes; 5. Patients with symptoms of nerve compression caused by various causes; 6. At the same time, patients who receive other neuroprotective therapy, including nerve growth factor, vitamin B and calcium-magnesium mixture; 7. Patients who were treated with oxaliplatin for chemotherapy before; 8. Patients who need radiotherapy within half a year after operation; 9. Pregnant or lactation period women; 10. Patients with cognitive impairment or psychosis; 11. Other patients the investigator considers unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| incidence of chronic neurotoxicity | 3 years | Differences in the incidence of chronic neurotoxicity of grade 2 and above during and after treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time of occurrence of chronic toxicity | 3 years | Time of occurrence of chronic toxicity to grade 2 and 3 |
| main symptoms | 3 years | Incidence and severity of main symptoms |
| Recovery time of neurotoxicity | 3 years | Recovery time of grade 2 and 3 neurotoxicity |
| incidence of acute neurotoxicity | 3 years | Difference in the incidence of acute neurotoxicity |
| myelosuppression | 3 years | Incidence of myelosuppression |
| nausea, vomiting, diarrhea, and hand-foot syndrome | 3 years | Incidence of nausea, vomiting, diarrhea, and hand-foot syndrome |
| Cumulative dose of oxaliplatin and the proportion of patients | 3 years | Cumulative dose of oxaliplatin and the proportion of patients who stop using oxaliplatin because of neurotoxicity |
Countries
China
Contacts
Primary ContactChen Haibo, PhD
Backup ContactGu Yanhong, PhD
Outcome results
None listed